Minimizing second cancer risk following radiotherapy: Current perspectives

Cancer Management and Research

Volumn 7, Issue , 2014, Pages 1-11

  Ng, John ^a   Shuryak, Igor ^b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

Genetic biomarkers; Radiation; Radiation techniques; Radiation toxicities; Radiobiology modeling; Second cancer risk; Secondary carcinogenesis

Indexed keywords

AGING; BLADDER CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM TUMOR; COLON CANCER; EVIDENCE BASED MEDICINE; GENE MUTATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HEALTH CARE UTILIZATION; HIGH RISK POPULATION; HODGKIN DISEASE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG CANCER; NONHUMAN; PROTON THERAPY; RADIATION DOSE; REVIEW; RISK FACTOR; RISK REDUCTION; SECOND CANCER; STEREOTACTIC BODY RADIATION THERAPY; STOMACH CANCER; THYROID CANCER;

EID: 84919662670     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S47220     Document Type: Review

References (88)

1. Preston DL, Ron E, Tokuoka S, et al. Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res. 2007;168:1-64.
2. Metayer C, Lynch CF, Clarke EA, et al. Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol. 2000;18:2435-2443.
3. Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst. 2005;97:1428-1437.
4. Lorigan P, Radford J, Howell A, Thatcher N. Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. Lancet Oncol. 2005;6:773-779.
5. Bernstein JL, Haile RW, Stovall M, et al; WECARE Study Collaborative Group. Radiation exposure, the ATM gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study. J Natl Cancer Inst. 2010;102(7):475-483.
6. Best T, Li D, Skol AD. Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. Nat Med. 2011;17(8):941-943.
7. Shuryak I, Hahnfeldt P, Hlatky L, Sachs RK, Brenner DJ. A new view of radiation-induced cancer: integrating short- and long-term processes. Part I: approach. Radiat Environ Biophys. 2009;48:263-274.
8. Shuryak I, Hahnfeldt P, Hlatky L, Sachs RK, Brenner DJ. A new view of radiation-induced cancer: integrating short- and long-term processes. Part II: second cancer risk estimation. Radiat Environ Biophys. 2009;48:275-286.
9. Shuryak I, Sachs RK, Brenner DJ. A new view of radiation-induced cancer. Radiat Prot Dosimetry. 2011;143:358-364.
10. Joosten A, Bochud F, Moeckli R. A critical evaluation of secondary cancer risk models applied to Monte Carlo dose distributions of 2-dimensional, 3-dimensional conformal and hybrid intensity-modulated radiation therapy for breast cancer. Phys Med Biol. 2014;59(16):4697-4722.
11. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2010. Bethesda: National Cancer Institute; 2013.
12. Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27:2328-2338.
13. Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med. 1996;334(12):745-751.
14. Morton LM, Onel K, Curtis RE. The rising incidence of second cancers: patterns of occurrence and identification of risk factors for children and adults. Am Soc Clin Oncol Educ Book. 2014;34:e57-e67.
15. Friedman DL, Whitton J, Leisenring W, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2010;102:1083-1095.
16. Wolden SL, Lamborn KR, Cleary SF, Tate DJ, Donaldson SS. Second cancers following pediatric Hodgkin's disease. J Clin Oncol. 1998;16:536-544.
17. Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst. 1993;85:25-31.
18. Brooks JD, Boice JD Jr, Stovall M, et al; WECARE Collaborative Group. Reproductive status at first diagnosis influences risk of radiation-induced second primary contralateral breast cancer in the WECARE study. Int J Radiat Oncol Biol Phys. 2012;84(4):917-924.
19. Brooks JD, Teraoka SN, Reiner AS, et al; WECARE Study Collaborative Group. Variants in activators and downstream targets of ATM, radiation exposure, and contralateral breast cancer risk in the WECARE study. Hum Mutat. 2012;33:158-164.
20. Bernstein JL, Thomas DC, Shore RE, et al; WECARE Study Collaborative Group. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report. Eur J Cancer. 2013;49:2979-2985.
21. Pierce LJ, Haffty BG. Radiotherapy in the treatment of hereditary breast cancer. Semin Radiat Oncol. 2011;21(1):43-50.
22. Kirova YM, Gambotti L, De Rycke Y. Risk of second malignancies after adjuvant radiotherapy for breast cancer: a large-scale, single-institution review. Int J Radiat Oncol Biol Phys. 2007;68(2):359-363.
23. Brenner DJ, Curtis RE, Hall EJ, Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer. 2000;88(2):398-406.
24. Liauw SL, Sylvester JE, Morris CG. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up. Int J Radiat Oncol Biol Phys. 2006;66(3):669-673.
25. Boice JD Jr, Day NE, Andersen A. Second cancers following radiation treatment for cervical cancer. An international collaboration among cancer registries. J Natl Cancer Inst. 1985;74(5):955-975.
26. ICRP. Recommendations of the International Commission on Radiological Protection. Ann ICRP. 2007;37:2-4.
27. BEIR. Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII, Phase 2. Washington, DC: National Academy of Science; 2006.
28. Intensity Modulated Radiation Therapy Collaborative Working Group. Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys. 2001;51(4):880-914.
29. Griem KL, Fetherston P, Kuznetsova M. Three-dimensional photon dosimetry: a comparison of treatment of the intact breast in the supine and prone position. Int J Radiat Oncol Biol Phys. 2003;57(3):891-899.
30. Ng J, Shuryak I, Xu Y. Predicting the risk of secondary lung malignancies associated with whole-breast radiation therapy. Int J Radiat Oncol Biol Phys. 2012;83(4):1101-1106.
31. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys. 2006;65(1):1-7.
32. Hall EJ. The impact of protons on the incidence of second malignancies in radiotherapy. Technol Cancer Res Treat. 2007;6(Suppl 4):31-34.
33. Hall EJ, Wuu CS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys. 2003;56(1): 83-88.
34. Constine LS, Tarbell N, Hudson MM. Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose. Int J Radiat Oncol Biol Phys. 2008;72(1):24.
35. Johnstone PA, McMullen KP, Buchsbaum JC. Pediatric CSI: are protons the only ethical approach? Int J Radiat Oncol Biol Phys. 2013;87(2):228-230.
36. Wolden SL. Protons for craniospinal radiation: are clinical data important? Int J Radiat Oncol Biol Phys. 2013;87(2):231-232.
37. Shuryak I, Sachs RK, Brenner DJ. Cancer risks after radiation exposure in middle age. J Natl Cancer Inst. 2010;102(21):1628-1636.
38. Nordling CO. A new theory on the cancer inducing mechanism. Br J Cancer. 1953;7:68-72.
39. Armitage P, Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer. 1954;VIII:1-12.
40. Nilsson P, Thames HD, Joiner MC. A generalized formulation of the 'incomplete-repair' model for cell survival and tissue response to fractionated low dose-rate irradiation. Int J Radiat Biol. 1990;57(1):127-142.
41. Thames HD. An 'incomplete-repair' model for survival after fractionated and continuous irradiations. Int J Radiat Biol Relat Stud Phys Chem Med. 1985;47(3):319-339.
42. Dale RG. The application of the linear-quadratic model to fractionated radiotherapy when there is incomplete normal tissue recovery between fractions, and possible implications for treatments involving multiple fractions per day. Br J Radiol. 1986;59(705):919-927.
43. Sontag W. A discrete cell survival model including repair after high dose-rate of ionizing radiation. Int J Radiat Biol. 1997;71(2):129-144.
44. Lange CS, Mayer PJ, Reddy NM. Tests of the double-strand break, lethal-potentially lethal and repair-misrepair models for mammalian cell survival using data for survival as a function of delayed-plating interval for log-phase Chinese hamster V79 cells. Radiat Res. 1997;148(3):285-292.
45. Zaider M, Wuu CS. The effects of sublethal damage recovery and cell cycle progression on the survival probability of cells exposed to radioactive sources. Br J Radiol. 1995;68(805):58-63.
46. Stewart RD. Two-lesion kinetic model of double-strand break rejoining and cell killing. Radiat Res. 2001;156(4):365-378.
47. Curtis SB. Lethal and potentially lethal lesions induced by radiation - a unified repair model. Radiat Res. 1986;106(2):252-270.
48. Tobias CA. The repair-misrepair model in radiobiology: comparison to other models. Radiat Res Suppl. 1985;8:S77-S95.
49. Radivoyevitch T, Kozubek S, Sachs RK. Biologically based risk estimation for radiation-induced CML. Inferences from BCR and ABL geometric distributions. Radiat Environ Biophys. 2001;40(1):1-9.
50. Hahnfeldt P, Hlatky L. Resensitization due to redistribution of cells in the phases of the cell cycle during arbitrary radiation protocols. Radiat Res. 1996;145(2):134-143.
51. Hahnfeldt P, Hlatky L. Cell resensitization during protracted dosing of heterogeneous cell populations. Radiat Res. 1998;150(6):681-687.
52. Mebust M. Testing extrapolation of a biologically based exposure-response model from in vitro to in vivo conditions. Regul Toxicol Pharmacol. 2002;35(1):72-79.
53. Schollnberger H. Nonlinear dose-response relationships and inducible cellular defence mechanisms. J Radiol Prot. 2002;22(3A):A21-A25.
54. Hofmann W. Modeling lung cancer incidence in rats following exposure to radon progeny. Radiat Prot Dosimetry. 2006;122(1-4): 345-348.
55. Sachs RK, Brenner DJ. Solid tumor risks after high doses of ionizing radiation. Proc Natl Acad Sci U S A. 2005;102(37):13040-13045.
56. Sachs RK. Second cancers after fractionated radiotherapy: stochastic population dynamics effects. J Theor Biol. 2007;49(3):518-531.
57. Shuryak I. Radiation-induced leukemia at doses relevant to radiation therapy: modeling mechanisms and estimating risks. J Natl Cancer Inst. 2006;98(24):1794-1806.
58. Little MP. A multi-compartment cell repopulation model allowing for inter-compartmental migration following radiation exposure, applied to leukaemia. J Theor Biol. 2007;245(1):83-97.
59. Schneider U, Kaser-Hotz B. Radiation risk estimates after radiotherapy: application of the organ equivalent dose concept to plateau dose-response relationships. Radiat Environ Biophys. 2005;44(3):235-239.
60. Schneider U, Walsh L. Cancer risk estimates from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy. Radiat Environ Biophys. 2008;47(2):253-263.
61. Bennett J, Little MP, Richardson S. Flexible dose-response models for Japanese atomic bomb survivor data: Bayesian estimation and prediction of cancer risk. Radiat Environ Biophys. 2004;43(4):233-245.
62. Dasu A. The use of risk estimation models for the induction of secondary cancers following radiotherapy. Acta Oncol. 2005;44(4):339-347.
63. Gray LH. Radiobiology and cancer. Nature. 1957;179(4568):991-994.
64. Wheldon EG, Lindsay KA, Wheldon TE. The dose-response relationship for cancer incidence in a two-stage radiation carcinogenesis model incorporating cellular repopulation. Int J Radiat Biol. 2000;76(5):699-710.
65. Lindsay KA. Radiation carcinogenesis modelling for risk of treatment-related second tumours following radiotherapy. Br J Radiol. 2001;74(882):529-536.
66. Armitage P. Multistage models of carcinogenesis. Environ Health Perspect. 1985;63:195-201.
67. Moolgavkar SH. Multistage models for carcinogenesis. J Natl Cancer Inst. 1980;65(2):215-216.
68. Moolgavkar SH. The multistage theory of carcinogenesis and the age distribution of cancer in man. J Natl Cancer Inst. 1978;61(1):49-52.
69. Moolgavkar SH, Knudson AJ Jr. Mutation and cancer: a model for human carcinogenesis. J Natl Cancer Inst. 1981;66(6):1037-1052.
70. Sachs RK. Modeling intercellular interactions during carcinogenesis. Radiat Res. 2005;164(3):324-331.
71. Little MP, Li G. Stochastic modelling of colon cancer: is there a role for genomic instability? Carcinogenesis. 2007;28(2):479-487.
72. Little MP, Wright EG. A stochastic carcinogenesis model incorporating genomic instability fitted to colon cancer data. Math Biosci. 2003;183(2):111-134.
73. Pierce DA, Mendelsohn ML. A model for radiation-related cancer suggested by atomic bomb survivor data. Radiat Res. 1999;152(6):642-654.
74. Pierce DA, Vaeth M. Age-time patterns of cancer to be anticipated from exposure to general mutagens. Biostatistics. 2003;4(2):231-248.
75. Ritter G. The multistage model of cancer development: some implications. Toxicol Ind Health. 2003;19(7-10):125-145.
76. Yakovlev A, Polig E. A diversity of responses displayed by a stochastic model of radiation carcinogenesis allowing for cell death. Math Biosci. 1996;132(1):1-33.
77. Heidenreich WF, Hoogenveen R. Limits of applicability for the deterministic approximation of the two-step clonal expansion model. Risk Anal. 2001;21(1):103-105.
78. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68(4):820-823.
79. Heidenreich WF. Promoting action of radiation in the atomic bomb survivor carcinogenesis data? Radiat Res. 2007;168(6):750-756.
80. Heidenreich WF. Two-step model for the risk of fatal and incidental lung tumors in rats exposed to radon. Radiat Res. 1999;151(2):209-217.
81. Heidenreich WF. Multistage models and the incidence of cancer in the cohort of atomic bomb survivors. Radiat Res. 2002;158(5):607-614.
82. Heidenreich WF, Paretzke HG. The two-stage clonal expansion model as an example of a biologically based model of radiation-induced cancer. Radiat Res. 2001;156(5 pt 2):678-681.
83. Pompei F, Polkanov M, Wilson R. Age distribution of cancer in mice: the incidence turnover at old age. Toxicol Ind Health. 2001;17(1):7-16.
84. Brunet A, Rando TA. Aging: from stem to stern. Nature. 2007; 449(7160):288-291.
85. Carlson ME, Conboy IM. Loss of stem cell regenerative capacity within aged niches. Aging Cell. 2007;6(3):371-382.
86. Sharpless NE, DePinho RA. How stem cells age and why this makes us grow old. Nat Rev Mol Cell Biol. 2007;8(9):703-713.
87. Pompei F, Wilson R. A quantitative model of cellular senescence influence on cancer and longevity. Toxicol Ind Health. 2002;18(8): 365-376.
88. Harding C. Cancer suppression at old age. Cancer Res. 2008;68(11): 4465-4478.